The present invention relates to a topical composition containing a probiotic and hyaluronic acid or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of inflammatory bowel disease.

The present invention relates to a topical composition containing a probiotic and hyaluronic acid or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of inflammatory bowel disease.

The present invention aims to provide a method for producing a microneedle device comprising a coating comprising dexmedetomidine and isoproterenol, in which the stability of isoproterenol during production and after production of the microneedle device is high. A method for producing a microneedle device according to one embodiment of the present invention comprises coating microneedles with a coating liquid to form a coating on the microneedles. The microneedle device comprises a substrate, microneedles disposed on the substrate, and a coating formed on the microneedles. The coating liquid comprises dexmedetomidine or a pharmaceutically acceptable salt thereof, isoproterenol or a pharmaceutically acceptable salt thereof, ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof, and a sulfated polysaccharide.

The present invention aims to provide a method for producing a microneedle device comprising a coating comprising dexmedetomidine and isoproterenol, in which the stability of isoproterenol during production and after production of the microneedle device is high. A method for producing a microneedle device according to one embodiment of the present invention comprises coating microneedles with a coating liquid to form a coating on the microneedles. The microneedle device comprises a substrate, microneedles disposed on the substrate, and a coating formed on the microneedles. The coating liquid comprises dexmedetomidine or a pharmaceutically acceptable salt thereof, isoproterenol or a pharmaceutically acceptable salt thereof, ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof, and a sulfated polysaccharide.

Disclosed herein are methods of producing aqueous dispersions comprising insoluble alpha-glucan having at least 50% alpha-1,3 glycosidic linkages. For example, in addition to dispersing insoluble alpha-glucan that has never been dried, methods are disclosed for effectively dispersing insoluble alpha-glucan that has previously been dried. Further disclosed are aqueous dispersions comprising insoluble alpha-glucan, such as those produced by the disclosed methods. Aqueous dispersions of the present disclosure have enhanced features of viscosity, stability, and particle size distribution, for example. Application of aqueous dispersions in various products and uses are also disclosed.

Disclosed herein are methods of producing aqueous dispersions comprising insoluble alpha-glucan having at least 50% alpha-1,3 glycosidic linkages. For example, in addition to dispersing insoluble alpha-glucan that has never been dried, methods are disclosed for effectively dispersing insoluble alpha-glucan that has previously been dried. Further disclosed are aqueous dispersions comprising insoluble alpha-glucan, such as those produced by the disclosed methods. Aqueous dispersions of the present disclosure have enhanced features of viscosity, stability, and particle size distribution, for example. Application of aqueous dispersions in various products and uses are also disclosed.

The present invention relates to solid pharmaceutical compositions comprising N-[1-(5-cyano-pyridin-2−ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or pharmaceutically acceptable salt thereof. The invention further relates to methods for manufacturing said compositions and their uses for the treatment or prevention of diseases and disorders linked to T-type calcium channels such as epilepsy.

The present invention relates to solid pharmaceutical compositions comprising N-[1-(5-cyano-pyridin-2−ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or pharmaceutically acceptable salt thereof. The invention further relates to methods for manufacturing said compositions and their uses for the treatment or prevention of diseases and disorders linked to T-type calcium channels such as epilepsy.

In one aspect, thermal energy storage compositions are described herein. In some embodiments, a composition comprises 0.5-10 wt. % polysaccharide and 88-99.5 wt. % water, wherein the weight percentages are based on the total weight of the composition. Moreover, in some cases, the composition is shape stable at 20° C. and 1 atm.

In one aspect, thermal energy storage compositions are described herein. In some embodiments, a composition comprises 0.5-10 wt. % polysaccharide and 88-99.5 wt. % water, wherein the weight percentages are based on the total weight of the composition. Moreover, in some cases, the composition is shape stable at 20° C. and 1 atm.